STOCKTON, CALIFORNIA/March 8 , 2013 / Newswire/ — Viratech Corp. (OTC: VIRA), the first open source biotech research social network platform, announced today the signing of an agreement for an exclusive license from Health Care Intellectual Properties, LLC to Viratech, Corp, for United States Provisional Patent Application 61696297, titled “Method of Treating Breast Disease.”
Breast cancer is a common cancer in women. Early diagnosis and treatments are vital for better outcomes. This formula consists of an anti-disease, anti-cancer formula with a technology designed for the treatment breast disease, including cancer. The patent was created to address a need to prevent the formation of cancer or precursors to cancer such as atypia or other states of abnormal breast tissue.
Dr. Buckman, the CEO of Viratech, states, “There is a great need to help treat breast disease, especially early breast disease states. If we can demonstrate a decrease in the number of women that get cancer or even help delay the activity of the disease in future clinical trials, it would be a great step in non-invasive therapy and breast cancer prevention.”
Health Care Intellectual Properties is the holding company for Dr. Buckman’s patents licensed to Viratech on an exclusive basis. This will also allow Viratech to sub-license this technology to other companies.
Dr. Buckman has written a variety of books: Find and Stop Breast Cancer, Find and Stop Diabetes, Find and Stop Body Imbalances, The Wellness Index, and other health related topics.
Viratech has a platform that can help with new technologies for licensing, sublicensing, promotion, business development, and marketing. Using this model, Viratech anticipates sublicensing of the technologies from this agreement to support its model of light-touch, low overhead, and making a positive impact in the field of breast cancer. Viratech is interested in using its open-source research platform to further research in this field.
About Viratech Corp.
Viratech Corp. has created the first open source biotech research social network platform. The purpose of the platform is to make it possible for individuals or smaller companies to compete with larger companies in the race to patent new medicines or technology. This has been made possible by leveraging social collaboration in a way that allows new biotech ventures the ability to protect their intellectual property, then simultaneously allowing those same ventures the ability to promote and crowdsource their development.
Forward-Looking Statements:
This press release includes forward-looking statements concerning the future performance of our business, its operations and its financial performance and condition, and also includes selected operating results presented without the context of accompanying financial results. These forward-looking statements include, among others, statements with respect to our objectives and strategies to achieve those objectives, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates or intentions. These forward-looking statements are based on our current expectations. We caution that all forward-looking information is inherently uncertain and actual results may differ materially from the assumptions, estimates or expectations reflected or contained in the forward-looking information, and that actual future performance will be affected by a number of factors, including economic conditions, technological change, regulatory change and competitive factors, many of which are beyond our control. Therefore, future events and results may vary significantly from what we currently foresee. We are under no obligation (and we expressly disclaim any such obligation) to update or alter the forward-looking statements whether as a result of new information, future events or otherwise.
Contact: Dr. Kevin Buckman
Viratech, Corp.
http://viratech.org
Email Contact: info@viratech.org
209-477-3030